Spectrum Asset Management Inc. NB CA Purchases 619 Shares of Pfizer Inc. $PFE

Spectrum Asset Management Inc. NB CA raised its position in Pfizer Inc. (NYSE:PFE) by 3.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,679 shares of the biopharmaceutical company’s stock after purchasing an additional 619 shares during the quarter. Spectrum Asset Management Inc. NB CA’s holdings in Pfizer were worth $429,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. bought a new position in Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter valued at $28,000. Horizon Financial Services LLC bought a new stake in Pfizer during the 1st quarter worth about $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 0.6%

Shares of Pfizer stock opened at $26.27 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business has a fifty day simple moving average of $24.76 and a two-hundred day simple moving average of $24.14. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a market capitalization of $149.36 billion, a price-to-earnings ratio of 13.97, a P/E/G ratio of 0.86 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PFE. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Finally, Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.